A new report from IQVIA Institute for Human Data Science estimates that of 7,310 prescription drugs legally dispensed to U.S. patients between January 2017 to December 2022, roughly 70% (5,085) were being actively marketed and sold by illegal online pharmacies.

A new survey from Wolters Kluwer Health reflects increasing trust in providers in non-traditional primary care settings.

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.

Members of an FDA advisory panel voted in support of Pfizer’s respiratory syncytial virus (RSV) vaccine (Abrysvo) for the prevention of RSV in infants via administration to pregnant women.

Findings from a study published in NEJM suggest that a key treatment for opioid use disorder is underprescribed among patients in the United States, in particular among Black patients.